Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Prostate Cancer
PROSTATE ADVISOR
FEATURED CONTENT
-
-
Claims-Based Survival Models Have Potential to Aid Prostate Cancer Decision Making
“Most men with early-stage prostate cancer will die with their disease, not from their disease,” Dr Murphy said. -
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Current Research Into Pain Assessment
Immunotherapy for Prostate Cancer
Targeted Agents
Targeted Agents (cont.)
Radium-223
Chemotherapy
Immunotherapy
Treatment Sequencing
Androgen Deprivation Therapy
Duration of ADT
Docetaxel in Combination With ADT
HSD3B1 Allele Inheritance Linked With ADT Resistance
ADT and Radiation
Predictions for the Future
PROSTATE CANCER NEWS
Morbidity Low With Focal Laser Ablation of Prostate Cancer
Agent Orange Possibly Protective in Prostate Cancer ADT Recipients
Biparametric MRI May Suffice for Prostate Cancer Detection
Investigating CD133 as a Biomarker of Prostate Cancer Disparity in African American Men
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
